


Product Name : Mubritinib
Cat. No. : PC-20781
CAS No. : 366017-09-6
Molecular Formula : C₂₅H₂₃F₃N₄O₂
Molecular Weight : 468.47
Target : EGFR
Solubility : 10 mM in DMSO



CAS: 366017-09-6

Biological Activity

Mubritinib (TAK-165) is a potent inhibitor of human epidermal growth factor receptor 2 (HER2, ERBB2) tyrosine kinase with IC₅₀ of 6 nM, also is a potent Complex I inhibitor with IC₅₀ of 51 nM.

Mubritinib (TAK-165) does not inhibit other types tyrosine kinase up to 25,000 nM.

Mubritinib (TAK-165) inhibits HER2 phosphorylation and its down-stream Akt and MAPK in HER2 strongly expressing cells (BT474 breast cancer cell line).

Mubritinib (TAK-165) shows synergistic effect with trametinib in KRAS-mutant cell lines.

Mubritinib exhibits strong anti-leukemic effects in vitro and in vivo, functions through ubiquinone-dependent inhibition of electron transport chain (ETC) complex I activity.

Mubritinib (TAK-165) inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo.

References

Nagasawa J, et al. Int J Urol. 2006 May;13(5):587-92.

Bacelli I, et al. Cancer Cell. 2019 Jul 8;36(1):84-99.e8.

Ding Xue, et al. J Med Chem. 2022 Jan 13;65(1):343-368.

Uitdehaag JC, et al. PLoS One. 2015 May 27;10(5):e0125021.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com